Kenalog-10 (Triamcinolone Acetonide)
Brand Names: Kenalog-10
Methodology & AI Transparency ⓘ
Kenalog-10 (Triamcinolone Acetonide) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Kenalog-10 (Triamcinolone Acetonide) represents a prescription brand-name corticosteroid entry registered by E.R.
- 2 Real-world patient consensus: Branded corticosteroid presentation of Triamcinolone Acetonide (E.R. Squibb & Sons, L.L.C.); generic reference: /meds/triamcinolone-acetonide.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $175.66 cash mean against $465.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Kenalog-10 (Triamcinolone Acetonide)): peripheral edema (4.2%), palpitations (3.2%), nausea (8.9%).
Ask our AI Specialists anything about Kenalog-10 (Triamcinolone Acetonide)
Kenalog-10 (Triamcinolone Acetonide) Mechanism, CYP450 Pathways & DailyMed Monograph
Kenalog-10 (Triamcinolone Acetonide) represents a prescription brand-name corticosteroid entry registered by E.R. Squibb & Sons, L.L.C. with package codes 0003-0494, 50090-0295. Reviewed against 2024-08-26 FDA SPL standards (10 mg/mL Injection, Suspension; 0.10% Tube of Paste), clinical deployment addresses The intra-articular or soft tissue administration of KENALOG-10 Injection (triamcinolone acetonide injectable suspension,.
Kenalog-10 achieves therapeutic action via Triamcinolone Acetonide, engaging corticosteroid physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 10 mg/mL Injection, Suspension; 0.10% Tube of Paste (registered by E.R. Squibb & Sons, L.L.C., NDC 0003-0494, 50090-0295), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Kenalog-10 ($465.50 retail) with generic Triamcinolone Acetonide ($175.66 low cash).
Clinical clearance of Kenalog-10 (Triamcinolone Acetonide) (Corticosteroid) relies on predominantly hepatic biotransformation with renal elimination of polar kenalog-10 (triamcinolone acetonide) conjugates with a Steady-state plasma equilibrium reached over 9–20 hour t½ intervals for Kenalog-10 (Triamcinolone Acetonide) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Kenalog-10 (Triamcinolone Acetonide) (10 mg/mL Injection, Suspension) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after kenalog-10 (triamcinolone acetonide) administration.
FDA clinical labeling for Kenalog-10 (Triamcinolone Acetonide) restricts administration in contraindicated in patients with prior serious allergic response to kenalog-10 (triamcinolone acetonide) (ndc 0003-0494); severe baseline organ impairment where triamcinolone acetonide accumulation exceeds safe therapeutic margins across 10 mg/mL Injection, Suspension, 0.10% Tube of Paste, 0.10% Tube of Cream, 0.05% Jar of Ointment, 0.10% Bottle of Lotion, with self-reported patient tracking dominated by nausea (8.9% of reports), headache (8.4% of reports), fatigue (5.7% of reports).
Electrolyte retention and renal perfusion changes are more likely when Kenalog-10 (Triamcinolone Acetonide) overlaps with RAAS blockade.
Reconcile eGFR-adjusted medications before escalating Kenalog-10 (Triamcinolone Acetonide) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Kenalog-10 (Triamcinolone Acetonide) (NDC 0003-0494)
- Severe baseline organ impairment where Triamcinolone Acetonide accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (22 Reports)
Kenalog-10 (Triamcinolone Acetonide) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kenalog-10 (Triamcinolone Acetonide))
Human clinical trial evidence for Kenalog-10 (Triamcinolone Acetonide) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Kenalog-10 (Triamcinolone Acetonide) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3216/unit (~$69.65/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $465.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $175.66 / mo | View logs ↓ |
Kenalog-10 (Triamcinolone Acetonide) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Kenalog-10 (Triamcinolone Acetonide) RxNorm Concept ID | 1085750 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3216 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $465.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $175.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Kenalog-10 (Triamcinolone Acetonide) Patient Community, Cohort Filters & Dosage Logs
Deterministic Kenalog-10 (Triamcinolone Acetonide) reference combining NIH RxNorm (1085750), Medicaid NADAC ($2.3216/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Kenalog-10 (Triamcinolone Acetonide) community threads and patient logs by age, biological sex, dosage, and treatment duration.